<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:During the course of investigation of a suspected abdominal aortic aneurysm in a 57-year-old woman, a solid 6 × 5 cm mass is detected in the right kidney. The abdominal aorta reveals no abnormalities. The patient is feeling well and has no history of any serious illness or medication usage. She is a 25-pack-year smoker. Her vital signs are within normal limits. Physical examination reveals no abnormalities. Biopsy of the mass shows renal cell carcinoma. Contrast-enhanced CT scan indicates no abnormalities involving contralateral kidney, lymph nodes, lungs, liver, bone, or brain. Which of the following treatment options is the most appropriate next step in the management of this patient?? A: Interferon-ɑ IFN-ɑ, B: Interleukin 2 IL-2, C: Nephrectomy, D: Radiation, E: Sunitinib,  <response>: Based on the information provided in the question stem, this patient has a solid mass in her right kidney that has been diagnosed as renal cell carcinoma via biopsy. She has no evidence of metastases based on imaging. The question asks for the most appropriate next step in management.Choice A IFN-α and Choice B IL-2 are types of immunotherapy that may have a role in metastatic renal cell carcinoma, but are not first-line treatments. Choice D radiation may have a role as an adjuvant therapy after nephrectomy, but is not a primary treatment. Choice C nephrectomy is the surgical removal of the kidney containing the tumor. This is the standard first-line treatment for localized renal cell carcinoma in a patient who is a surgical candidate.Choice E sunitinib is a tyrosine kinase inhibitor used for metastatic renal cell carcinoma. Since this patient has localized disease with no evidence of metastases, sunitinib would not be appropriate.Therefore, the most appropriate next step in management is nephrectomy Choice C.C: Nephrectomy 